IDEXX Laboratories (NASDAQ:IDXX) Vs. ABT, MDT, ISRG, SYK, EW, BDX, BSX, DXCM, BAX, and RMD
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), DexCom (DXCM), Baxter International (BAX), and ResMed (RMD). These companies are all part of the "health care equipment" industry.
IDEXX Laboratories vs.
IDEXX Laboratories (NASDAQ:IDXX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
Medtronic received 1053 more outperform votes than IDEXX Laboratories when rated by MarketBeat users. Likewise, 79.16% of users gave Medtronic an outperform vote while only 73.71% of users gave IDEXX Laboratories an outperform vote.
IDEXX Laboratories has a net margin of 23.89% compared to Medtronic's net margin of 12.29%. IDEXX Laboratories' return on equity of 115.28% beat Medtronic's return on equity.
84.7% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 79.6% of Medtronic shares are owned by institutional investors. 2.1% of IDEXX Laboratories shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Medtronic had 14 more articles in the media than IDEXX Laboratories. MarketBeat recorded 19 mentions for Medtronic and 5 mentions for IDEXX Laboratories. Medtronic's average media sentiment score of 0.23 beat IDEXX Laboratories' score of -0.06 indicating that Medtronic is being referred to more favorably in the news media.
IDEXX Laboratories has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Medtronic has higher revenue and earnings than IDEXX Laboratories.
IDEXX Laboratories currently has a consensus price target of $675.00, suggesting a potential upside of 6.27%. Medtronic has a consensus price target of $144.55, suggesting a potential upside of 13.15%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than IDEXX Laboratories.
Summary
Medtronic beats IDEXX Laboratories on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip ChartIDEXX Laboratories (NASDAQ:IDXX) vs. Its Competitors
IDEXX Laboratories Competitors List
